SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Zonagen (zona) - good buy?
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: khrnyc who wrote (1987)1/23/1998 3:36:00 AM
From: khrnyc  Read Replies (3) of 7041
 
And finally, a few questions:

1) With p values of 0.01 and 0.001 in the two US trials, the studies seem statistically significant to me. Both were double blinded, placebo controlled, and one added a crossover component. What specifically do people object to in the study design and results?

2) If data from the phase III trials were meaningless, why did four major pharma companies (each of which did independent due diligence in reviewing both the trials and the patent applications) ALL submit term sheets to Zona? If it were really nonsense would all four independently submit term sheets?

3) If the lawsuit referred to in Asencio's Jan 9, 1998 "press release"
was known to SGP in July of 1995; and in fact the claims were legitamate; and this therefore means that zona is illigitamate; why did SGP do the Vasomax deal?

4)Investor relations at SGP assured me that Zona's patent applications
had been scrutinized by a team from SGP. What specifically is it about the patents that people feel limit the patent and/or make it unenforceable? Please, no platitutes like "its just plain 'ol generic phentolamine" and "phentolamine has no role in ED"

5) With what frequency does SGP make investments of this kind and magnitude (actual numbers would be helpful). I know of at least one example where they made a deal with an "infamous" company (ICN) that is working out quite well. ICN's rebetol (in combination with Intron A) is now awaiting approval at the FDA for the treatment of hepatitis C.

Come on, let's try for some meaningful discourse.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News